Cardiovascular safety of Janus Kinase inhibitor therapy in a multi-ethnic population.

IF 1.5 Q3 RHEUMATOLOGY

Musculoskeletal Care Pub Date : 2023-12-14 DOI:10.1002/msc.1853

Kehinde Sunmboye, Tom Petrie, Maumer Durrani

{"title":"Cardiovascular safety of Janus Kinase inhibitor therapy in a multi-ethnic population.","authors":"Kehinde Sunmboye, Tom Petrie, Maumer Durrani","doi":"10.1002/msc.1853","DOIUrl":null,"url":null,"abstract":"Background: Janus Kinase (JAK) inhibitors are a class of drugs that have been shown to be effective in treating a variety of autoimmune rheumatic diseases (ARDs). However, there have been concerns about their potential to increase the risk of cardiovascular events. Some studies have found no ethnic differences. This study aimed to assess the cardiovascular safety of JAK inhibitor therapy in a large multi-ethnic patient cohort and to identify if there is a correlation between the age of patients in the cohort with an increased risk of cardiovascular events.Methods: This retrospective cross-sectional study enrolled 309 patients with ARDs who were treated with JAK inhibitors. Cardiovascular events that occurred while on JAK inhibitor therapy were identified retrospectively.Results: The mean age of the study cohort was 59.3 years, and 73% were Caucasian and 25% were South Asian in ethnicity. There was a positive and statistically significant correlation between cardiovascular events and age of the patients (rpb = 0.12, n = 309, p = 0.036), but the correlation was weak based on the rpb value of 0.12.Conclusion: The results of this study suggest that JAK inhibitor therapy is generally safe in older patients with ARDs in a multi-ethnic population. However, further research is needed to identify any other patient factors that may increase the risk of cardiovascular events. The findings of this study could also have practise implications in the use of JAK inhibitor therapy in patients over 65 years of age.","PeriodicalId":46945,"journal":{"name":"Musculoskeletal Care","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2023-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Musculoskeletal Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/msc.1853","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Janus Kinase (JAK) inhibitors are a class of drugs that have been shown to be effective in treating a variety of autoimmune rheumatic diseases (ARDs). However, there have been concerns about their potential to increase the risk of cardiovascular events. Some studies have found no ethnic differences. This study aimed to assess the cardiovascular safety of JAK inhibitor therapy in a large multi-ethnic patient cohort and to identify if there is a correlation between the age of patients in the cohort with an increased risk of cardiovascular events.

Methods: This retrospective cross-sectional study enrolled 309 patients with ARDs who were treated with JAK inhibitors. Cardiovascular events that occurred while on JAK inhibitor therapy were identified retrospectively.

Results: The mean age of the study cohort was 59.3 years, and 73% were Caucasian and 25% were South Asian in ethnicity. There was a positive and statistically significant correlation between cardiovascular events and age of the patients (rpb = 0.12, n = 309, p = 0.036), but the correlation was weak based on the rpb value of 0.12.

Conclusion: The results of this study suggest that JAK inhibitor therapy is generally safe in older patients with ARDs in a multi-ethnic population. However, further research is needed to identify any other patient factors that may increase the risk of cardiovascular events. The findings of this study could also have practise implications in the use of JAK inhibitor therapy in patients over 65 years of age.

查看原文本刊更多论文

多种族人群中 Janus 激酶抑制剂治疗对心血管的安全性。

背景：Janus 激酶（JAK）抑制剂是一类已被证明能有效治疗各种自身免疫性风湿病（ARD）的药物。然而，人们一直担心它们可能会增加心血管事件的风险。一些研究没有发现种族差异。本研究旨在评估JAK抑制剂治疗在大型多种族患者队列中的心血管安全性，并确定队列中患者的年龄与心血管事件风险增加之间是否存在相关性：这项回顾性横断面研究共纳入了309名接受JAK抑制剂治疗的ARD患者。结果：研究队列中的平均年龄为 35 岁：研究队列的平均年龄为 59.3 岁，73% 为白种人，25% 为南亚人。心血管事件与患者年龄之间存在统计学意义上的正相关（rpb = 0.12，n = 309，p = 0.036），但基于 0.12 的 rpb 值，相关性较弱：本研究结果表明，在多种族人群中，JAK抑制剂治疗对老年ARD患者总体上是安全的。但是，还需要进一步研究，以确定可能增加心血管事件风险的其他患者因素。这项研究的结果还可能对65岁以上患者使用JAK抑制剂治疗产生实际影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Musculoskeletal Care RHEUMATOLOGY-

CiteScore

2.30

自引率

7.70%

发文量

期刊介绍： Musculoskeletal Care is a peer-reviewed journal for all health professionals committed to the clinical delivery of high quality care for people with musculoskeletal conditions and providing knowledge to support decision making by professionals, patients and policy makers. This journal publishes papers on original research, applied research, review articles and clinical guidelines. Regular topics include patient education, psychological and social impact, patient experiences of health care, clinical up dates and the effectiveness of therapy.